Myelo Therapeutics GmbH is developing a small molecule that could provide a cheaper and safer alternative to standard of care G-CSF to prevent and to treat chemotherapy-induced neutropenia.

Neutropenia is a decrease in levels of the neutrophil subset of white blood cells required to fight infection. It is caused by diseases or drugs, including chemotherapy, that impair neutrophil production in the bone marrow or destroy neutrophils in circulation.